Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 Mg Once Daily Vs. 1 Mg Twice Daily Budesonide Orodispersible Tablets for Induction of Histological Remission in Adults with Eosinophilic Esophagitis

Next Previous
X
Search
Trial Profile

Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 Mg Once Daily Vs. 1 Mg Twice Daily Budesonide Orodispersible Tablets for Induction of Histological Remission in Adults with Eosinophilic Esophagitis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Registrational; Therapeutic Use
  • Acronyms EOS-4
  • Sponsors Dr Falk Pharma

    • Most Recent Events

    • 19 Sep 2024 Planned number of patients changed from 242 to 308.
    • 10 May 2021 New trial record
    • 10 May 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top